Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives

SIMPLE SUMMARY: For patients with advanced prostate cancer, many different treatment options are available. One option is the radioligand therapy with (177)Lutetium labelled prostate-specific membrane antigen (Lu-PSMA). This treatment showed good results in previous studies with only some non-severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Seitzer, Konstantin Egon, Seifert, Robert, Kessel, Katharina, Roll, Wolfgang, Schlack, Katrin, Boegemann, Martin, Rahbar, Kambiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371469/
https://www.ncbi.nlm.nih.gov/pubmed/34359614
http://dx.doi.org/10.3390/cancers13153715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371469/
https://www.ncbi.nlm.nih.gov/pubmed/34359614
http://dx.doi.org/10.3390/cancers13153715

Ejemplares similares